CervoMed (CRVO) News Today

Chardan Capital began coverage on shares of CervoMed in a report on Wednesday. They issued a "buy" rating and a $55.00 price target for the company.

CervoMed (NASDAQ:CRVO) Trading Up 1.2%

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) was the recipient of a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 1,010,000 shares, an increase of 46.2% from the July 31st total of 690,700 shares. Currently, 18.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 78,600 shares, the days-to-cover ratio is presently 12.8 days.

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 690,700 shares, an increase of 14.8% from the July 15th total of 601,700 shares. Currently, 12.9% of the shares of the company are short sold. Based on an average trading volume of 70,300 shares, the short-interest ratio is presently 9.8 days.

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Research analysts at Brookline Capital Management boosted their FY2024 earnings estimates for CervoMed in a research report issued on Monday, August 12th. Brookline Capital Management analyst T. Bussian now expects that the company will post earnings pe

CervoMed (NASDAQ:CRVO - Get Free Report) issued its earnings results on Monday. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). The business had revenue of $3.29 million during the quarter, compared to analyst estimates of $3.48 million. CervoMed had a negative net margin of 38.30% and a negative return on equity of 58.63%.

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totalling 601,700 shares, a growth of 71.6% from the June 30th total of 350,700 shares. Approximately 11.3% of the company's stock are short sold. Based on an average daily volume of 56,500 shares, the days-to-cover ratio is currently 10.6 days.

Canaccord Genuity Group reissued a "buy" rating and issued a $65.00 price objective on shares of CervoMed in a report on Thursday.

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) saw a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 350,700 shares, an increase of 92.8% from the June 15th total of 181,900 shares. Based on an average daily trading volume, of 50,000 shares, the short-interest ratio is currently 7.0 days. Currently, 6.6% of the shares of the company are short sold.

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Investment analysts at Brookline Capital Management issued their Q2 2024 earnings estimates for shares of CervoMed in a research report issued on Monday, July 8th. Brookline Capital Management analyst T. Bussian anticipates that the company will post ea

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 126,500 shares, a growth of 144.2% from the April 30th total of 51,800 shares. Currently, 2.4% of the company's stock are sold short. Based on an average daily volume of 24,600 shares, the short-interest ratio is presently 5.1 days.

Cwm LLC acquired a new position in shares of CervoMed Inc. (NASDAQ:CRVO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 38,253 shares of the company's stock, value

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 25,700 shares, a growth of 24.8% from the March 31st total of 20,600 shares. Based on an average trading volume of 29,500 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.7% of the company's stock are short sold.

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Analysts at Zacks Small Cap boosted their FY2024 EPS estimates for CervoMed in a note issued to investors on Wednesday, April 10th. Zacks Small Cap analyst D. Bautz now anticipates that the company will earn ($1.13) per share for the year, up from their

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Equities research analysts at Zacks Small Cap issued their Q1 2024 earnings estimates for CervoMed in a research report issued on Wednesday, April 10th. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings per share of ($0.46

Canaccord Genuity Group raised their target price on shares of CervoMed from $50.00 to $65.00 and gave the stock a "buy" rating in a research note on Monday.

CervoMed (NASDAQ:CRVO) will be releasing earnings on Friday, March 22, Yahoo Finance reports.